STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
STRATEC Biomedical AG (SRBZF) - Total Assets
Latest total assets as of September 2024: $450.84 Million USD
Based on the latest financial reports, STRATEC Biomedical AG (SRBZF) holds total assets worth $450.84 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
STRATEC Biomedical AG - Total Assets Trend (2014–2023)
This chart illustrates how STRATEC Biomedical AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
STRATEC Biomedical AG - Asset Composition Analysis
Current Asset Composition (December 2023)
STRATEC Biomedical AG's total assets of $450.84 Million consist of 53.2% current assets and 46.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.2% |
| Accounts Receivable | $58.06 Million | 12.4% |
| Inventory | $142.62 Million | 30.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $62.13 Million | 13.3% |
| Goodwill | $51.16 Million | 11.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how STRATEC Biomedical AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: STRATEC Biomedical AG's current assets represent 53.2% of total assets in 2023, a decrease from 65.3% in 2014.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2023, down from 33.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 21.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 30.6% of total assets.
STRATEC Biomedical AG Competitors by Total Assets
Key competitors of STRATEC Biomedical AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
STRATEC Biomedical AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - STRATEC Biomedical AG generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, STRATEC Biomedical AG generates $ 2.80 in net profit.
STRATEC Biomedical AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.52 | 2.28 | 1.12 |
| Quick Ratio | 0.93 | 0.85 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $142.13 Million | $ 124.72 Million | $ 11.03 Million |
STRATEC Biomedical AG - Advanced Valuation Insights
This section examines the relationship between STRATEC Biomedical AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.4% |
| Total Assets | $466.58 Million |
| Market Capitalization | $675.78K USD |
Valuation Analysis
Below Book Valuation: The market values STRATEC Biomedical AG's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: STRATEC Biomedical AG's assets grew by 17.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for STRATEC Biomedical AG (2014–2023)
The table below shows the annual total assets of STRATEC Biomedical AG from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $466.58 Million | +17.38% |
| 2022-12-31 | $397.50 Million | +7.86% |
| 2021-12-31 | $368.52 Million | +11.03% |
| 2020-12-31 | $331.90 Million | +25.83% |
| 2017-12-31 | $263.78 Million | +2.25% |
| 2016-12-31 | $257.97 Million | +62.31% |
| 2015-12-31 | $158.94 Million | +15.38% |
| 2014-12-31 | $137.75 Million | -- |